• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Sihuan Pharmaceutical Holdings Group (SEHK:460) Looks Pricey On 2026 Earnings Guidance

    Simply Wall St·07/28/2026 10:25:27
    語音播報

    Sihuan Pharmaceutical Holdings Group (SEHK:460) has issued new earnings guidance for the first half of 2026, indicating a significant increase in net profit supported by medical aesthetics, drug commercialization progress, associate profits and asset restructuring gains.

    See our latest analysis for Sihuan Pharmaceutical Holdings Group.

    The earnings guidance arrives after a mixed period for Sihuan Pharmaceutical Holdings Group, with the share price at HK$0.93, a 1 month share price return of 12.05% but a year to date share price return that has declined 27.34%. The 3 year total shareholder return is positive and the 5 year total shareholder return shows a sizeable decline. This points to improving short term momentum against a weaker longer term record as investors reassess growth prospects and risks around the medical aesthetics and drug businesses.

    If this earnings update has you looking beyond a single stock, it could be a useful moment to scan the wider healthcare technology theme through 127 healthcare AI stocks. This can help you spot other companies where the market is reacting to new product or earnings news.

    Bulls point to Sihuan Pharmaceutical Holdings Group’s profit guidance and medical aesthetics strength. Bears focus on the longer term share price record and asset sales. Which side does the current valuation actually support?

    Price-to-Earnings of 40.3x: Is it justified?

    Sihuan Pharmaceutical Holdings Group trades on a P/E of 40.3x, which suggests the share price is reflecting a high level of earnings expectations at the current HK$0.93.

    The P/E ratio compares the company’s share price to its earnings per share. For a healthcare group that has only recently become profitable, a higher P/E often points to the market placing weight on forecast growth rather than current earnings.

    Analysts currently expect earnings to grow 49.23% per year and revenue to grow 21.7% per year. Against that, our DCF model estimate of future cash flow value is HK$0.13 per share, which is far below the current share price. The P/E is also materially higher than both the estimated fair P/E of 31.2x and the Hong Kong Pharmaceuticals industry average of 14.4x, which indicates the valuation is rich compared to both the model and peers.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Preferred multiple of 40.3x price-to-earnings (OVERVALUED)

    However, there is still a risk that weaker long term returns and reliance on medical aesthetics could leave Sihuan Pharmaceutical Holdings Group exposed if sentiment or segment demand cools.

    Find out about the key risks to this Sihuan Pharmaceutical Holdings Group narrative.

    Another View on Sihuan Pharmaceutical Holdings Group’s Value

    Our DCF model points to a future cash flow value of about HK$0.13 per share, which sits well below the current HK$0.93 price. That implies Sihuan Pharmaceutical Holdings Group screens as overvalued on this approach and raises the question of how much earnings optimism is already in the price.

    Look into how the SWS DCF model arrives at its fair value.

    460 Discounted Cash Flow as at Jul 2026
    460 Discounted Cash Flow as at Jul 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sihuan Pharmaceutical Holdings Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 248 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    If the mixed signals around Sihuan Pharmaceutical Holdings Group leave you unsure, move quickly to review the underlying data and form your own view using the 2 key rewards.

    Looking for more investment ideas beyond Sihuan Pharmaceutical Holdings Group?

    Do not stop with Sihuan Pharmaceutical Holdings Group. Use this moment to scan fresh ideas that match your goals so you are not relying on a single story.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.